Paclitaxel based chemotherapy

DRUG2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

ChemoradiationChemotherapy EffectEsophageal CancerEsophagogastric Juction CancerEsophagogastric Junction CancerEsophagus CancerImmunotherapySurgery

Phase 3

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

RecruitingNCT04821778

Cancer Institute and Hospital, Chinese Academy of Medical SciencesChemoradiation, Chemotherapy Effect, Esophagogastric Junction Cancer +3

Start: 2002-01-01End: 2030-12-31Target: 2000Updated: 2026-01-21

Neoadjuvant Treatment Modalities in Esophageal Cancer

RecruitingNCT04821843

Cancer Institute and Hospital, Chinese Academy of Medical SciencesChemoradiation, Chemotherapy Effect, Esophageal Cancer +4

Start: 2002-01-01End: 2030-12-31Target: 2000Updated: 2026-01-21

Related Papers

Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study

Cancer Biology & Therapy2025-05-142 citations